AC immune SA: Taking research into development
An increasing number of start-up companies are setting out to seize the attractive business opportunities offered by pharmaceutical research and biotechnology in particular. Yet, the road to success is long, expensive and highly uncertain. The case takes a look at the development and strategies of AC Immune SA, a biotech start-up performing research into Alzheimer’s cures. Following a successful B-financing round, the company’s management identified three strategic tasks to take the venture further: (1) Master the transition from a research to a development organization, given the existing resource constraints. (2) Build a value-optimized product portfolio while keeping options open. (3) Adjust partner or licensing strategies to the latest financial situation to allow for maximum value creation.While discussing the case and how best to tackle the three identified challenges, students will specifically learn about the success factors of leading a small venture through the stormy and uncertain terrain outlined in the case.
May 2005
Cranfield University
Wharley End Beds MK43 0JR, UK
Tel +44 (0)1234 750903
Email [email protected]
Harvard Business School Publishing
60 Harvard Way, Boston MA 02163, USA
Tel (800) 545-7685 Tel (617)-783-7600
Fax (617) 783-7666
Email [email protected]
NUCB Business School
1-3-1 Nishiki Naka
Nagoya Aichi, Japan 460-0003
Tel +81 52 20 38 111
Email [email protected]
IMD retains all proprietary interests in its case studies and notes. Without prior written permission, IMD cases and notes may not be reproduced, used, translated, included in books or other publications, distributed in any form or by any means, stored in a database or in other retrieval systems. For additional copyright information related to case studies, please contact Case Services.
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD 14 August 2023